Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CASR | P41180 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43735 | 1.00 | AOC3 (0.57) | AOC3L3MBTL1CASRCHRM2CHRM1 | |
| SCHEMBL343726 | 1.00 | AOC3 (0.57) | AOC3L3MBTL1CASRCHRM2CHRM1 | |
| SCHEMBL2608969 | 0.86 | AOC3 (0.58) | AOC3L3MBTL1CASRCHRM2CHRM1 | |
| SCHEMBL6912472 | 0.85 | PTGS1 (0.58) | AOC3L3MBTL1UGT2B7ACHE | |
| SCHEMBL6912468 | 0.85 | PTGS1 (0.58) | AOC3L3MBTL1UGT2B7ACHE | |
| SCHEMBL2093768 | 0.85 | AOC3 (0.59) | AOC3L3MBTL1CASRCHRM2CHRM1 | |
| SCHEMBL2087869 | 0.85 | AOC3 (0.59) | AOC3L3MBTL1CASRCHRM2CHRM1 | |
| SCHEMBL11604883 | 0.85 | AOC3 (0.62) | AOC3L3MBTL1CASRCHRM2CHRM1 | |
| SCHEMBL24925808 | 0.84 | AOC3 (0.54) | AOC3L3MBTL1CASRCHRM2CHRM1 | |
| SCHEMBL18793772 | 0.84 | AOC3 (0.54) | AOC3L3MBTL1CASRCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110002961-B | Method for racemization-free synthesis of chiral alcohol | 三峡大学 | 2022-05-03 | — | — | CN | claimed |
| CN-105039429-A | Method for biologically producing (S)-metoxybenzene alcohol | UNIV QINGDAO SCIENCE & TECHNOLOGY | 2015-11-11 | — | — | CN | claimed |
| CN-117003699-A | Etomidate derivative and preparation method and application thereof | 江苏恩华药业股份有限公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-110002961-B | Method for racemization-free synthesis of chiral alcohol | 三峡大学 | 2022-05-03 | — | — | CN | disclosed |
| EP-2582799-B1 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (S)-3-(1-AMINOETHYL)-PHENOL | CODEXIS INC (US) | 2017-12-20 | — | — | EP | disclosed |
| CN-105039429-A | Method for biologically producing (S)-metoxybenzene alcohol | UNIV QINGDAO SCIENCE & TECHNOLOGY | 2015-11-11 | — | — | CN | disclosed |
| US-8932838-B2 | Biocatalysts and methods for the synthesis of (S)-3-(1-aminoethyl)-phenol | CODEXIS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140356944-A1 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (S)-3-(1-AMINOETHYL)-PHENOL | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2014-12-04 | — | — | US | disclosed |
| US-8852900-B2 | Biocatalysts and methods for the synthesis of (S)-3-(1-aminoethyl)-phenol | CODEXIS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2582799-A2 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (S)-3-(1-AMINOETHYL)-PHENOL | Codexis, Inc. (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20130089898-A1 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (S)-3-(1-AMINOETHYL)-PHENOL | CODEXIS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2011159910-A2 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (S)-3-(1-AMINOETHYL)-PHENOL | CODEXIS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-1934159-B1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF SE (DE) | 2009-03-25 | — | — | EP | disclosed |
| US-20090030235-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF SE (DE) | 2009-01-29 | — | — | US | disclosed |
| EP-1934159-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF SE (DE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007036570-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2007-04-05 | — | — | WO | disclosed |
| US-7108896-B2 | Method of increasing helical twisting power, optically active compound, liquid crystal compostion containing the same, and liquid crystal display device | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20040021128-A1 | Method of increasing helical twisting power, optically active compound, liquid crystal composition containing the same, and liquid crystal display device | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2004-02-05 | — | — | US | disclosed |
| US-6365398-B1 | REACTING RACEMIC CARBOXYLIC ACID ESTER WITH RACEMIC ALCOHOL IN PRESENCE OF A CARBOXYL ESTER HYDROLASE | BASF AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |
| EP-1031629-A2 | Method of preparation of stereoisomeric carboxylic acid esters | BASF AKTIENGESELLSCHAFT (DE) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030235-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | ADH5, ADH1C, ADH1A | AOC3 725/4885L3MBTL1 4634/4885CASR 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.